This dual targeting approach triggers the release of damage-associated molecular patterns (DAMPs), enhances tumor immunogenicity, and synergizes with PD-L1 blockade to achieve complete tumor regression in preclinical models [159]. The gene discussed is CD274; the disease is neoplasm.